Latest Articles

Publication Date
Preliminary Evaluation of Leuprorelin Acetate Microspheres Plus Levonorgestrel-Releasing Intrauterine System in Endometriosis: An Exploratory Study Focusing on BNIP3 and EPAC1 Expression.

This exploratory pilot study aimed to assess the preliminary clinical effects of leuprorelin acetate microspheres for injection [gonadotropin-releasing hormone agonist (GnRH-a)] combined with levonorgestrel-releasing intrauterine system (LNG-IUS) in treating endometriosis …

Published: May 14, 2026, midnight
[Investigation of pharmacological regimens combined with focused ultrasound ablation surgery for alleviating dysmenorrhea in extrinsic adenomyosis].

Objective: To investigate optimal long-term medication regimens combined with focused ultrasound ablation surgery (FUAS) for alleviating dysmenorrhea in patients with extrinsic adenomyosis. Methods: A retrospective research enrolled patients with extrinsic …

Published: April 29, 2026, midnight
Adenomyosis Pathophysiology, Diagnostic Advances, and Therapeutic Options.

Adenomyosis is a heterogeneous, nonmalignant uterine disorder characterized by ectopic endometrium within the myometrium, leading to abnormal uterine bleeding, dysmenorrhea, chronic pelvic pain, and subfertility. Once considered a disease of …

Published: April 2, 2026, midnight
Characteristics and Preoperative Management of Adolescent Patients With Pathology-Confirmed Endometriosis: A Multi-Institutional Study.

Endometriosis affects an estimated 25% to 75% of adolescent patients with chronic pelvic pain; the diagnosis is made surgically and treatment typically consists of hormone suppression and pain management strategies. …

Published: Jan. 19, 2026, midnight
Uterine Serous Carcinoma Following the Insertion of Levonorgestrel Int | IJWH - Dove Medical Press

Uterine Serous Carcinoma Following the Insertion of Levonorgestrel Int | IJWH Dove Medical Press

Published: Nov. 4, 2025, 10:26 a.m.
Michelle Wise, MD, discusses levonorgestrel IUD offering effective endometrial protection during hormone therapy - Contemporary OB/GYN

Michelle Wise, MD, discusses levonorgestrel IUD offering effective endometrial protection during hormone therapy Contemporary OB/GYN

Published: Oct. 23, 2025, 8:33 p.m.
Racial and Ethnic Differences in Risk for Hysterectomy Following Insertion of a Levonorgestrel-releasing Intra-uterine device: A Retrospective Cohort Study.

Evidence regarding risk for hysterectomy following treatment for benign gynecological conditions with a Levonorgestrel-releasing intrauterine device (LNG-IUD) is limited. We assess whether race and ethnicity are associated with hysterectomy risk …

Published: July 31, 2025, midnight
Association Between Levonorgestrel-Releasing Intrauterine System Exposure Duration and Breast Cancer Incidence.

To investigate the association between the duration of levonorgestrel-releasing intrauterine system (LNG-IUS) use and breast cancer risk in Korean women.

Published: March 13, 2025, midnight
Subdermal implants vs. levonorgestrel intrauterine devices outcomes in reproductive-aged women: a systematic review and meta-analysis.

We aimed to conduct a systematic review and meta-analysis comparing the outcomes of subdermal implants and levonorgestrel intrauterine system (LNG-IUS) in reproductive-aged women.

Published: March 11, 2025, midnight
Women's experience, satisfaction, and continuation with the levonogestrel-containing intrauterine system: A cross-sectional study.

The levonorgestrel-containing intrauterine system (LNG-IUS) is a safe, long-acting, reversible contraceptive method. This study aimed to examine women's experiences, satisfaction, and continuation with the levonorgestrel-containing intrauterine system. This cross-sectional study …

Published: Feb. 20, 2025, 12:15 a.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!